We have isolated and sequenced a C-terminally amidated peptide from bovine striatum. The peptide was purified to homogeneity by adsorption to XAD-2 resins and four different HPLC steps. Amino acid composition analysis and gas-phase sequence analysis revealed identity of this peptide with residues 8-26 of the proenkephalin-derived opioid peptide amidorphin, which we have recently isolated from bovine adrenal medulla. C-terminal amidation of amidorphin-(8-26) from bovine striatum was demonstrated by its stability to carboxypeptidase A digestion and full crossreactivity in a radioimmunoassay that required the C-terminal amide group as part of the recognition site. The nonopioid peptide amidorphiu-(8-26), which lacks the N-terminal [Met] (proopiomelanocortin). The genes of these precursors have been isolated and sequenced (1-9). What peptide or peptides are produced and secreted by a cell, however, is a function not only of the particular mRNAs expressed in the cell but also of the production and distribution of specific enzymes involved in the post-translational proteolytic processing of the peptide precursors. These post-translational mechanisms are tissue specific and may, thus, enable the selective liberation of a particular set of bioactive peptides from a precursor containing more than one biologically active sequence.
Several neuropeptide precursor proteins have recently been discovered that contain sequences of more than one bioactive peptide. Striking examples of this type of precursor are the three opioid peptide precursors proopiomelanocortin, proenkephalin (= proenkephalin A), and prodynorphin (= proenkephalin B). They contain either multiple opioid peptide sequences (proenkephalin and prodynorphin) or one opioid peptide copy together with bioactive nonopioid peptides (proopiomelanocortin). The genes of these precursors have been isolated and sequenced (1) (2) (3) (4) (5) (6) (7) (8) (9) . What peptide or peptides are produced and secreted by a cell, however, is a function not only of the particular mRNAs expressed in the cell but also of the production and distribution of specific enzymes involved in the post-translational proteolytic processing of the peptide precursors. These post-translational mechanisms are tissue specific and may, thus, enable the selective liberation of a particular set of bioactive peptides from a precursor containing more than one biologically active sequence.
Here we present the isolation and sequence of a Cterminally amidated peptide from bovine striatum. It consists of residues 8-26 of the proenkephalin-derived opioid peptide amidorphin, which we have recently isolated from bovine adrenal medulla (10) . Thus, amidorphin- (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) lacks the N-terminal [Metlenkephalin copy of amidorphin. In contrast to amidorphin, the nonopioid peptide amidorphin-(8-26) does not occur in the adrenal medulla, but it is a major product of the opioid peptide precursor proenkephalin in the brain. This is an example of the tissue-specific processing of a precursor.
METHODS
Preparation and Properties of the Amidorphin Antiserum. To generate an antiserum to amidorphin, the synthetic peptide (custom synthesis by Peninsula Laboratories, San Carlos, CA) was linked to bovine thyroglobulin by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimidefHCl and injected into a male New Zealand White rabbit, as described in detail (10) . The resulting antiserum was used in the RIA; 1251 labeled synthetic amidorphin served as a tracer. The RIA procedure is described in detail elsewhere (11) . The highly specific antiserum requires the C-terminal amide group as a recognition site: on a molar basis, synthetic amidorphin- (20) (21) (22) (23) (24) (25) (26) crossreacted 100%, and synthetic amidorphin-(20-26)-OH (the nonamidated form) crossreacted 0.01%. Peptide F crossreacted 0.4%. All other peptides tested revealed a crossreactivity of less than 0.1%.
Isolation and Characterization of Amidorphin-(8-26). As starting material for the purification, 10 bovine brains were obtained from a local slaughterhouse and put on ice, within 15-30 min after death. The striata were dissected within 1 hr and boiled in 10 vol of 0.1 M HCO for 10 min. The tissue was homogenized in a blender and centrifuged for 60 min at 10,000 x g. The supernatant was treated with n-heptane to extract the lipids. The aqueous solution was acified with 20% trichloroacetic acid to a final concentration of 2% trichloroacetic acid and centrifuged at 15,000 x g for 60 min. The supernatant was then lyophilized to about 50% of the initial volume to remove the residual organic solvent and applied to a 300-ml column filled with XAD-2-adsorber resin (Serva, Heidelberg). After washing with water, the adsorbed substances were eluted with 600 ml of methanol. The methanol was removed at reduced pressure in a rotary evaporator. The resulting material was dissolved in 50 ml of 0.1% trifluoroacetic acid and adsorbed to a preparative Waters systems: (i) 50 mM NaH2PO4/5% (vol/vol) methanol, pH 7 .0/acetonitrile, Altex ODS 5-,um C18 column; (ii) 0.1% trifluoroacetic acid/acetonitrile, Altex RPSC C-3 column; (iii) 50 mM NaH2PO4/5% methanol, pH 2.7 (1 ml of concentrated H3PO4 per liter)/acetonitrile, Altex ODS 3-gm C18 column; and (iv) 0.1% trifluoroacetic acid/acetonitrile, Altex ODS 3-gm C18 column. The flow rate was 1.1 ml/min in i-iii and 1.0 ml/min in iv, and 0.5-ml fractions were collected.
Gas-phase sequence analysis was performed as described (10, 12) . For amino acid composition analysis, peptides were hydrolyzed in 6 M HCl containing 1% phenol. Amino acids were then derivatized with phenylisothiocyanate and analyzed by reverse-phase HPLC (phenylisothiocyanate amino acid analysis, ref. 13) .
For carboxypeptidase A digestion, a mixture of 200 pmol of purified amidorphin-(8-26) and 100 pmol of synthetic dynorphin A-(1-8) was dissolved in 1500 gl of 0.02 M Tris HCl/0.2 M NaCl/0.1% Triton X-100, pH 7.5. A suspension of 10 ,l of carboxypeptidase A (20 mg/ml) (Sigma type I) containing 200 ,g of enzyme was dissolved in 1 ml of 10% LiCl. Then 5 ul of the freshly prepared solution containing 1 ,g of enzyme was added to the peptide mixture and the sample was incubated at 37°C. Six 20-,ul aliquots were withdrawn, after 1, 5, 10, 60, 120, and 300 min. To terminate the enzyme reaction, each sample was incubated for 10 min at 96°C. Finally, the samples were each assayed in quintuplicate by RIA for immunoreactive amidorphin and dynorphin A-(1-8). Zero-time samples were withdrawn before addition of enzyme to determine the amount of peptide initially present in the sample. Dynorphin A-(1-8) was used as a control substance, because for this peptide a RIA specific for the C terminus of dynorphin A-(1-8) was available (14) . Separate samples of the peptide mixture with or without enzyme solution after inactivation at 96°C for 10 min were incubated for 300 min and assayed for immunoreactive peptides, to exclude the possibility of nonspecific degradation of the peptide during incubation.
Analysis of Amidorphin-Related Peptides in Bovine Tissue.
Bovine brains, pituitaries, and adrenals were obtained from a local slaughterhouse and placed on ice within 30 min after death. The brains were dissected within 1 hr into the various areas, the pituitaries were separated into anterior and posterior lobes (neural lobe with adhering intermediate lobe), and the adrenal cortex was separated from the adrenal medulla. Tissues were extracted as described above. This extraction procedure, yielding a recovery of more than 85% for 125I-labeled amidorphin, is superior to other extraction procedures, such as acid acetone in the presence of enzyme inhibitors or 2 M acetic acid (11) . After centrifugation, 2-g equivalents of pooled tissues from eight animals were used for gel filtration on a Sephadex G50 superfine column (1.6 x 90 cm). The fractions containing immunoreactive amidorphin were collected and, after lyophilization, treated with 3% (wt/vol) H202 for 30 min at 56°C, to oxidize the methionine residues of immunoreactive amidorphin. Subsequently, immunoreactive amidorphin was applied to an ODS C18 5-gm reverse-phase HPLC column (Altex, Berkeley, CA). It was eluted with 50 mM NaH2PO4/5% methanol, pH 7.0, and a linear gradient of acetonitrile from 0% to 30%o within 120 min, with a flow rate of 1.1 ml/min. The fraction size was 2.0 ml. Aliquots of each fraction were lyophilized and analyzed for their content of immunoreactive amidorphin.
RESULTS
Isolation and Structure of Amidorphin-(8-26). Amidorphin-(8-26) was purified to homogeneity from bovine striatum extracts, using the chromatographic steps described. Two separate purifications of 10 bovine striata each (about 220 g) were performed, yielding an average of 3 nmol of pure amidorphin-(8-26). Fig. 1 shows the absorbance and immunoreactive profiles of the analytical HPLC step iii. Both of the major UV-absorbing peaks were detected by the amidorphin antiserum, which was highly specific for the amidated C terminus of the peptide. These two peaks (A and B) were desalted in a final HPLC purification step (step iv).
Amino acid composition analysis and gas-phase sequence analysis of peak A and peak B revealed unambiguously that the primary sequences of the peptides in both peaks were identical to the sequence 8-26 of amidorphin and correspond to the sequence 112-129 of bovine proenkephalin. This is shown for peak A in Tables 1 and 2 .
The C-terminal amide group of peaks A and B was confirmed by carboxypeptidase A digestion experiments and by the immunological characteristics of these peptides, Endogenous peaks A and B from bovine striatum were completely stable for at least 300 min, whereas dynorphin A-(1-8), which was added together with peaks A and B to the enzyme mixture as a nonamidated control peptide, was completely digested by the enzyme within 5 min (see Fig. 2 for peak A). Moreover, peaks A and B exhibited full crossreactivity with the amidorphin antiserum that required the C-terminal amide residue as part of the recognition site.
Oxidation of peak A resulted in a shorter retention time on HPLC; this time was then identical to the retention time of peak B. Oxidation of peak B, however, did not alter the retention time of this peptide. Thus, we conclude that peak B represents the oxidized form of peak A, and that the full sequence of both peptides is Met-Asp-Glu-Leu-Tyr-Pro-LeuGlu-Val-Glu-Glu-Glu-Ala-Asn-Gly-Gly-Gly-Val-Leu-NH2. Since amidorphin-(8-26) contains a methionine residue, partial oxidation of this amino acid to methionine sulfoxide during the purification procedure is conceivable.
Regional Distribution of Amidorphin-Related Peptides. Amidorphin-related peptides were investigated in bovine adrenal medulla, posterior pituitary, and various brain areas by the combined use of a RIA specific for the C terminus of amidorphin, gel filtration, and HPLC. Amidorphin-related peptides were prepurified by gel filtration, in which they eluted in each case as a single immunoreactive peak (11) . Prior to HPLC, immunoreactive peaks were oxidized, as were peptides used for calibration ofthe HPLC columns. , determined with an antiserum that is highly specific for the C terminus of amidorphin and requires the C-terminal amide group in the recognition site. The peptide was prepurified by adsorbance to XAD-2 and HPLC as described in Methods. Prior to analysis of amino acid composition, peak A and peak B were desalted by HPLC. Glu 147 20 A 330-pmol portion of the purified peptide (peak A, Fig. 1 ) (determined by amino acid analysis) was loaded on an Applied Biosystem 470 A protein sequencer. Trifluoroacetic acid was used for conversion of anilinothiazolinone amino acids, and HPLC on an IBM-cyanopropyl column was used for identification of phenylthiohydantoin derivatives of amino acids. 3 shows the differential HPLC profiles of immunoreactive amidorphin in various tissues. In the adrenal medulla, the total amidorphin immunoreactivity was found to elute in the position of synthetic amidorphin, whereas amidorphin-(8-26) could not be detected. In the posterior pituitary, hypothalamus, midbrain, brainstem, and striatum, however, amidorphin-(8-26) was the predominant (in the striatum even the exclusive) form of immunoreactive amidorphin. [The identities of peaks 1 and 2 with amidorphin-(8-26) and amidorphin, respectively, were also demonstrated by use of a second HPLC system (data not shown).] Table 3 compares the concentrations of amidorphin with those of amidorphin- (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) , and shows a differential distribution of these two peptides in different tissues. Amidorphin-(8-26) could be detected in particularly high concentrations in the posterior pituitary, hypothalamus, and striatum.
To exclude the possibility of an artifactual formation of amidorphin-(8-26) from amidorphin as a consequence of postmortem degradation, we compared the ratio of amidorphin to amidorphin- (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) in various tissues at different times after death. Brains and pituitaries from 12 cows were put on ice within 30 min postmortem. Posterior pituitaries, hypothalami, and striata were dissected within 1 hr. One half of these tissues (i.e., pools of the respective areas from 6 cows) were immediately extracted, and the other half was extracted after 6 hr at room temperature. Amidorphinimmunoreactive peptides were analyzed by gel filtration and HPLC as described above. No change in the ratio of amidorphin to amidorphin-(8-26) between the different postmortem times could be observed in any of the three representative tissues investigated.
DISCUSSION
We have isolated and sequenced a C-terminally amidated peptide, amidorphin-(8-26), from bovine striatum. This nonopioid peptide can be considered a major product of the opioid peptide precursor proenkephalin in the brain, where it occurs in concentrations comparable to those of major opioid peptide products of this precursor, such as [Met] enkephalin, [Leu]enkephalin, and hepta-and octapeptide (15) . The sequence of amidorphin-(8-26) corresponds to the C-terminal portion of the opioid peptide amidorphin, which we have Only AM- (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) The total immunoreactive amidorphin (ir-AM) was measured after gel filtration of pooled tissue extracts (n = 8). Authentic amidorphin (AM) and amidorphin- (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) ] were determined by HPLC (see Fig. 3 ); values have been corrected for recovery losses. Tissue-specific processing of bovine proenkephalin. In the adrenal medulla, proenkephalin seems to be processed only to amidorphin. Amidorphin, which corresponds to residues i04-129, may be liberated from proenkephalin by proteolytic processing at the flanking basic Lys-Arg residues and subsequent transformation of the C-terminal Gly residue into an amide group (10) . However, in brain and posterior pituitary, as opposed to the adrenal medulla, amidorphin is obviously further processed at the Lys-Lys residues, giving rise to amidorphin-(8-26) and, possibly, [Met]enkephalin. peptide precursors but also of protein/(neuro-)peptide precursors in general (16) . Thus, in the brain, amidorphin obviously undergoes further proteolytic processing at these two lysine residues, giving rise to amidorphin-(8-26) and possibly [Met]enkephalin (Fig. 4) . The proenkephalin system in the brain might, therefore, be an example of a precursor in which an opioid peptide ([Met]enkephalin) is linked with a nonopioid peptide [amidorphin-(8-26)] of possibly different biological function. Such a model is known from proopiomelanocortin, which contains the opioid peptide -endorphin together with bioactive nonopioid peptides, such as corticotropin and a melanocyte-stimulating hormone (1). The physiological significance of amidorphin- (8-26) is not yet known. It is noteworthy, however, that this peptide contains a C-terminal amide group. This post-translational modification has been shown for several neuropeptides and hormones to be of essential importance for their biological activity-e.g., for corticotropin-releasing factor, gonadotropin-releasing factor, luteinizing hormone-releasing factor, a-melanocytestimulating hormone, cholecystokinin, and gastrin (17) . For example, the biological activity of the hypothalamic peptide corticotropin-releasing factor is decreased by a factor of 1000 after removal of its C-terminal amide group (18) .
-In the adrenal medulla, where the opioid peptide amidorphin occurs in remarkably high concentrations and is a majorproduct ofproenkephalin, amidorphin-(8-26) was not detectable. Conversely, the brain predominantly or exclusively (striatum) contains high concentrations of amidorphin-(8-26) but only minor amounts of amidorphin. This is indicative of tissue-specific processing of proenkephalin. Thus, in contrast to the brain, proenkephalin seems to be (19, 20) . A similarly high degree of tissue specificity in post-translational processing events has been demonstrated in detail for proopiomelanocortin and prodynorphin (21) (22) (23) (24) . Although less information is so far available for proenkephalin, recent studies (10) , including the present investigation, have begun to yield insights into the proteolytic processing of this precursor and may provide the basis for understanding the physiological significance of this system.
